SMILE techniques less disruptive

Article

Corneal biomechanical stability is better, less affected by flapless refractive procedure

The study included 60 eyes of 30 patients divided into two groups. The same femtosecond laser (VisuMax 500, Carl Zeiss Meditec) was used to create the LASIK flaps and the lenticule for the SMILE procedure, and the LASIK ablations were performed using a single excimer laser platform (WaveLight Allegretto, Alcon, Fort Worth, Texas, USA).

All LASIK flaps and SMILE caps had an attempted thickness of 90 μm. Corneal biomechanics were assessed using the Ocular Response Analyzer (ORA, Reichert, Munich, Germany) to measure corneal hysteresis (CH) and corneal resistance factor (CRF) at three months preoperatively and three months postoperatively.

Mean percent change in CH was –6.7% in the SMILE group and –17.4% in the femto-LASIK group. Mean percent change in CRF was –9.7% for the SMILE group and –22% for the femto-LASIK group. The reduction in CH did not correlate with the amount or percentage of corneal tissue removed nor with the optical zone or patient age.

"SMILE is a one-step, non-ablative corneal refractive procedure in which a lenticule of tissue is cut by the femtosecond laser and removed through a small incision," explained Dr Abdalla, cornea and refractive surgery senior fellow, Cornea Centre, Alexandria, Egypt. "This technique avoids recognized flap complications, including postoperative discomfort and dry eye, and as a flapless procedure, we consider SMILE the laser vision correction procedure of choice for patients involved in contact sports.

"In addition, based on our study, SMILE appears to offer better biomechanical stability than the flap-based procedure," continued Dr Abdalla. "However, further studies are warranted to confirm our findings, including in a larger patient population and ideally using better methods to evaluate corneal biomechanics."

Recent Videos
3 experts are featured in this series.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Vikas Chopra at AAO 2024: Advancements in MIGS are transforming patient care
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2024 MJH Life Sciences

All rights reserved.